( MENAFN - GlobeNewsWire - Nasdaq) LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare conference at 10:55 am ET on November 19, 2024.

A webcast of the presentation will be available here beginning at 10:55 am ET on Monday, November 18, 2024 and will be posted on the Investors section of the Company’s website. About Krystal Biotech,

LONDON--LivaNova PLC announced Vladimir Makatsaria, CEO, will present a general business update during fireside chats at Stifel, Wolfe and Piper in New York.

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to partic

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.

ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19,

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Stifel 2024 Healthcare Conference on Monday, 8, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:35 a.

Monday, November 18, 2024 at 2:25 pm ET Location: New York, NY A live webcast and archived replay of the fireside chat will be available on the investors section of About Vor Bio Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.